Chilean healthtech company Examedi has secured $750,000 in fresh capital in a funding round led by Platanus, with participation from existing board members. The transaction also includes the full exit of U.S. fund General Catalyst, marking a significant reshaping of the company’s cap table and investor base. The new round underpins Examedi’s strategy of profitable, moderate growth as it consolidates operations in Chile and scales in Mexico.
A New Phase for Examedi’s Business Model
Examedi operates a digital platform that brings diagnostic services directly to patients’ homes, managing everything from appointment scheduling to sample collection and delivery of test results. The model aims to replace the need for in-clinic visits in many routine cases, improving convenience for users and efficiency for laboratories and healthcare providers. The company views this at-home diagnostics infrastructure as a long-term, sustainable business rather than a short-lived pandemic-era play.
Post-Pandemic Reset and Operational Focus
Following the strong growth seen during the pandemic, Examedi struggled to maintain its earlier pace, which prompted a strategic reset. Former CEO and cofounder Ian Lee stepped down more than a year ago, and Argentine executive Mariano Werner, previously at Lemontech and Matrix Consulting, was brought in to “put the house in order.” Werner’s mandate has focused on removing excesses, tightening operations, and steering the company toward a more disciplined and efficiency-driven model.
Mexico and Chile on Diverging Trajectories
Today, Examedi’s operations are centered on two markets, Mexico and Chile, which are showing different dynamics. According to Werner, Mexico has been performing “super well,” posting growth of more than 80 percent over the past 12 months and reaching breakeven in October. Chile remains a core part of the business, but the company’s growth narrative is increasingly anchored in the Mexican operation and its path to profitability.
Leaner Team, Meritocratic Culture, and Revenue Targets
As part of the restructuring, Examedi has dramatically reduced its headcount from more than 160 employees at its peak to 26 today. Werner notes that most teams have been almost completely renewed, and he describes the current culture as strongly meritocratic, with what he calls a “really good” team in place. The company expects to close the year with approximately $4 million in revenue, supported by a more efficient structure and continued growth in demand for home-based diagnostics.
Funding Round, Valuation Reset, and Investor Alignment
The latest $750,000 round, led by Platanus and joined by current board members including Chilean entrepreneur Patrick Kiblisky, values Examedi at $17 million. This valuation is about 80 percent below the company’s previous peak, reflecting the broader market correction and the company’s pivot toward sustainable, profitability-focused growth. Founders Ian Lee, Andrés Kemeny, Juan Pablo Zepeda, and Alberto Albagli now hold a minority stake in common shares, while the new funding was structured with preferred shareholders, signaling a shift in control and governance.
Werner describes Examedi today as closer to a private equity style company, targeting annual growth of 50 to 60 percent while prioritizing profitability over hypergrowth. He argues that this profile no longer fits the mandate of investors such as General Catalyst, but is well aligned with the new shareholder base that favors attractive, efficient, and profitable businesses. With a lean team, a clearer focus on Mexico and Chile, and fresh capital to support operational improvements, Examedi is positioning itself for steady, disciplined expansion in Latin America’s evolving healthtech landscape.
Source: DF.CL